(Reuters) - Eli Lilly and Co (N:LLY) reported a 33% rise in fourth-quarter profit on Thursday, boosted by higher sales of its top-selling diabetes drug, Trulicity.
Net income rose to $1.50 billion (£1.1 billion), or $1.64 per share, in the quarter ended Dec. 31, from $1.13 billion, or $1.10 per share, a year earlier.
![](https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG0T13C_L.jpg)
Revenue rose to $6.11 billion from $5.64 billion.